WuXi Biologics Completes Topping Out of Singapore Drug Product Facility

Spanning approximately 30,000 square meters, the modular DP facility will feature advanced manufacturing lines, centralized Quality Control (QC) labs for full release and stability testing, and Manufacturing Science and Technology (MSAT) labs, significantly expanding the Company’s end-to-end DP capabilities. With three pre-filled syringe (PFS) lines and two vial lines for liquid and lyophilized products, it will deliver integrated DP manufacturing for multiple dosage forms across clinical and commercial stages. The facility will also incorporate green technologies, including solar panels and an advanced system for energy monitoring and analysis, reflecting WuXi Biologics’ commitment to sustainability. Operations are expected to commence in 2027.

Dr. Chris Chen, CEO of WuXi Biologics, said, “We are excited to celebrate another major milestone for our Singapore CRDMO hub. This achievement further reinforces our ability to provide global biopharmaceutical companies with a resilient and geographically diversified supply chain, one built on our world-class quality systems, cutting-edge innovation, and operational excellence. At the same time, we are dedicated to contributing to the local community in Singapore and the long-term development of its biopharmaceutical industry.”

Construction across the Singapore CRDMO hub continues to advance, with the drug substance facility currently in the design phase. The Hub marks a significant step in WuXi Biologics’ global extension and its long-term commitment as the partner of choice for global biopharmaceutical companies.

WuXi Biologics’ global manufacturing footprint spans China, the United States, Ireland, Germany, and Singapore, with 24 drug substance (DS) facilities and 18 drug product (DP) facilities currently in operation. This network provides integrated dual-sourcing solutions spanning DS and DP, from clinical development through commercial-scale manufacturing. As of 2025, WuXi Biologics had successfully passed 46 regulatory inspections worldwide, including 22 conducted by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), achieving a 100% success rate with no critical findings and no data integrity issues.